to evaluate the safety, tolerability, and efficacy of

AZD0486 monotherapy administered as an IV infusion in participants aged 12 years and

above with B-ALL with known CD19-expression by local laboratory technique, who are

either relapsed or refractory to ≥ 2 prior lines of therapy or to 1 prior line of therapy and the

participant is not eligible or has no other available standard treatment options.